A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 microg) delivered by the Respimat inhaler versus the free combination of tiotropium 5 microg and olodaterol 5 microg delivered by separate Respimat inhalers in patients with chronic obstructive pulmonary disease (COPD)

Trial Profile

A 4-week, randomised, double-blind, parallel group study to evaluate the efficacy and safety of tiotropium + olodaterol fixed dose combination (5/5 microg) delivered by the Respimat inhaler versus the free combination of tiotropium 5 microg and olodaterol 5 microg delivered by separate Respimat inhalers in patients with chronic obstructive pulmonary disease (COPD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Olodaterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 23 Feb 2017 Status changed from recruiting to completed.
    • 06 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2017.
    • 20 Oct 2016 Planned End Date changed from 8 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top